PRAN - Prana Biotechnology Ltd

Prana Biotechnology Limited (Prana) is an Australia-based company engaged in drug development and research. The focus of the Company is to develop disease modifying therapeutics for the treatment of common neurological disorders, with a focus upon Alzheimer's, Parkinson's and Huntington's diseases, specific cancers and age-related macular degeneration. It has developed a platform technology in association with internationally scientists and academic institutions, including The University of Melbourne, Massachusetts General Hospital and The Mental Health Research Institute of Victoria; and its research collaborators are The Buck Institute for Age Research, University of California and University College, London. As of June 30, 2010, the Company held interest in two subsidiaries: Prana Biotechnology Inc and Prana Biotechnology UK Ltd, and Prana's majority shareholder was National Limited.